** Shares of drug developer Summit Therapeutics SMMT.O rise 3% to $23.30
** AstraZeneca AZN.L is in talks to partner with Summit for up to $15 billion to license a lung cancer drug, ivonescimab, Bloomberg news reported, citing people familiar with the matter
** Summit is also talking to other major pharmaceutical companies about potential partnerships, the report said
** Summit did not immediately respond to Reuters' request seeking comment while an AstraZeneca spokesperson declined to comment
** Including session's move, stock up 25.6% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。